Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here

Cancer

Volumn 124, Issue 10, 2018, Pages 2086-2103

  Kwa, Maryann J ^a   Adams, Sylvia ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

checkpoint inhibitors; immunotherapy; programmed cell death 1 (PD 1) receptor; programmed death ligand 1 (PD L1); triple negative breast cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC MONOCLONAL ANTIBODY; ATEZOLIZUMAB; AVELUMAB; CANCER VACCINE; CAPECITABINE; CARBOPLATIN; CHECKPOINT INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; DURVALUMAB; ENTINOSTAT; EPIRUBICIN; ERIBULIN; GAMMA GLUTAMYLTRANSFERASE; GEMCITABINE; IPILIMUMAB; LACTATE DEHYDROGENASE; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PEPTIDE VACCINE; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; TICILIMUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINORELBINE TARTRATE; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PDCD1 PROTEIN, HUMAN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE LIVER FAILURE; ADRENAL INSUFFICIENCY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ASEPTIC MENINGITIS; ASTHENIA; AUTOIMMUNE HEPATITIS; BACKACHE; BREAST CANCER MOLECULAR SUBTYPE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CLINICAL OUTCOME; CRYOTHERAPY; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DEHYDRATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EARLY CANCER; FATIGUE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER; HYPERGLYCEMIA; HYPERTHYROIDISM; HYPONATREMIA; HYPOPHYSITIS; HYPOTENSION; HYPOTHYROIDISM; INTESTINE FLORA; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOCYTOPENIA; MICROSATELLITE INSTABILITY; MIGRAINE; MONOTHERAPY; MYALGIA; NAUSEA; NEOADJUVANT CHEMOTHERAPY; NEUTROPENIA; NONHUMAN; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; VOMITING; WEAKNESS; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DRUG EFFECT; FEMALE; IMMUNOLOGY; MORTALITY; PATHOLOGY; PROGNOSIS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B7-H1 ANTIGEN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 85041497790     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.31272     Document Type: Review

References (86)

1. Demaria S, Polones KA, Adams S. Cross-talk of breast cancer cells with the immune system. In: Gunduz M, ed. Breast Cancer: Carcinogenesis, Cell Growth and Signalling Pathways. Rijeka, Croatia: InTech; 2011:457-482.
2. Oble DA, Loewe R, Yu P, Mihm MC Jr Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma [serial online]. Cancer Immun. 2009;9:3.
3. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-1964.
4. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31:860-867.
5. Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from 2 phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959-2966.
6. Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25:1544-1550.
7. Dieci MV, Mathieu MC, Guarneri V, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in 2 phase III randomized adjuvant breast cancer trials. Ann Oncol. 2015;26:1698-1704.
8. Loi S, Drubay D, Adams S, et al. Pooled individual patient data analysis of stromal tumor infiltrating lymphocytes in primary triple negative breast cancer treated with anthracycline-based chemotherapy [abstract]. Cancer Res. 2016;76(4 suppl):S1-03.
9. Kwa M, Adams S. Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer. Curr Breast Cancer Rep. 2016;8:1-13.
10. Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol. 2016;2:1354-1360.
11. Safonov A, Jiang T, Bianchini G, et al. Immune gene expression is associated with genomic aberrations in breast cancer. Cancer Res. 2017;77:3317-3324.
12. Vonderheide RH, Domchek SM, Clark AS. Immunotherapy for breast cancer: what are we missing? Clin Cancer Res. 2017;23:2640-2646.
13. Mohammed ZM, Going JJ, Edwards J, Elsberger B, McMillan DC. The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. Br J Cancer. 2013;109:1676-1684.
14. Garcia-Martinez E, Gil GL, Benito AC, et al. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer [serial online]. Breast Cancer Res. 2014;16:488.
15. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2012;109:2796-2801.
16. Gu-Trantien C, Loi S, Garaud S, et al. CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013;123:2873-2892.
17. Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 2010;70:8368-8377.
18. Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259-271.
19. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
20. Gatalica Z, Snyder C, Maney T, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014;23:2965-2970.
21. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
22. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-2465.
23. Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2:361-370.
24. Cimino-Mathews A, Thompson E, Taube JM, et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Human Pathol. 2016;47:52-63.
25. Thompson E, Taube JM, Elwood H, et al. The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol. 2016;29:249-258.
26. Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T, Dermime S. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy [serial online]. BMC Cancer. 2008;8:57.
27. Schmid P, Cruz C, Braiteh FS, et al. Atezolizumab in metastatic TNBC (mTNBC): long-term clinical outcomes and biomarker analyses [abstract]. Cancer Res. 2017;77(13 suppl):2986.
28. Adams S, Schmid P, Rugo HS, et al. Phase 2 study of pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: KEYNOTE-086 cohort A [abstract]. J Clin Oncol. 2017;35(15 suppl);1088.
29. Adams S, Loi S, Toppmeyer D, et al. Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer [mTNBC]: preliminary data from KEYNOTE-086 cohort B [abstract]. J Clin Oncol. 2017;35(15 suppl);1088.
30. Adams S, Diamond JR, Hamilton EP, et al. Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC) [abstract]. J Clin Oncol. 2016;34(15 suppl):1009.
31. Tung N, Garber JE, Hacker MR, et al. Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer [serial online]. NPJ Breast Cancer. 2016;2:16002.
32. Bertucci F, Finetti P, Colpaert C, et al. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget. 2015;6:13506-13519.
33. Joneja U, Vranic S, Swensen J, et al. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. J Clin Pathol. 2017;70:255-259.
34. Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34:2460-2467.
35. Emens L, Braiteh, FS, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer [abstract]. Cancer Res. 2015;75(9 suppl):PD1-6.
36. Dirix L, Takacs I, Nikolinakos P, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib JAVELIN solid tumor trial [abstract]. Cancer Res. 2015;76(suppl 4):S1-04.
37. Tolaney SM, Savulsky C, Aktan G, et al. Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer [abstract]. Cancer Res. 2017;77(4 suppl):P5-15-02.
38. Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14:717-734.
39. Pfirschke C, Engblom C, Rickelt S, et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity. 2016;44:343-354.
40. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275-1281.
41. Nanda R, Liu MC, Yau C, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2 [abstract]. J Clin Oncol. 2017;35(15 suppl):506.
42. Schmid P, Park YH, Munoz-Couselo E, et al. Pembrolizumab + chemotherapy as neoadjuvant treatment for triple negative breast cancer (TNBC): preliminary results from KEYNOTE-173 [abstract]. J Clin Oncol. 2017;35(suppl);556.
43. Loibl S, Untch M, Burchardi N, et al. A randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab, a PD-L1 antibody, to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC) [abstract]. J Clin Oncol. 2017;35(15 suppl):3062.
44. Pusztai L, Silber A, Wysong Hofstatter E, et al. Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): a phase I/II trial [abstract]. J Clin Oncol. 2017;35(suppl);572.
45. Winer E, Dang T, Karantza V, et al. KEYNOTE-119: a randomized phase III study of single-agent pembrolizumab (MK-3475) vs single-agent chemotherapy per physician's choice for metastatic triple-negative breast cancer (mTNBC) [abstract]. J Clin Oncol. 2016;34(15 suppl):TPS1102.
46. Emens L, Adams S, Loi S, et al. IMpassion130: a phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC) [abstract]. J Clin Oncol. 2016;34(15 suppl);TPS1104.
47. Kwa M, Iwano A, Esteva FJ, et al. Phase II trial of pembrolizumab in combination with nab-paclitaxel in patients with metastatic HER2-negative breast cancer [abstract]. J Clin Oncol. 2017;35(15 suppl):TPS1124.
48. Emens LA. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther. 2012;12:1597-1611.
49. Benavides LC, Gates JD, Carmichael MG, et al. The impact of HER2/neu expression level on response to the E75 vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res. 2009;15:2895-2904.
50. Mittendorf EA, Clifton GT, Holmes JP, et al. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol. 2014;25:1735-1742.
51. Julien S, Picco G, Sewell R, et al. Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model. Br J Cancer. 2009;100:1746-1754.
52. Miles D, Roche H, Martin M, et al. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 2011;16:1092-1100.
53. Isakoff S, Tolaney SM, Tung NM, et al. A phase 1b study of safety and immune response to PVX-410 vaccine alone and in combination with durvalumab (MEDI4736) in HLA-A2+ patients following adjuvant therapy for stage 2/3 triple negative breast cancer [abstract]. J Clin Oncol. 2017;35(15 suppl):TPS1126.
54. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122-133.
55. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23-34.
56. Vonderheide RH, LoRusso PM, Khalil M, et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res. 2010;16:3485-3494.
57. Waitz R, Solomon SB, Petre EN, et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 2012;72:430-439.
58. McArthur HL, Diab A, Page DB, et al. A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling. Clin Cancer Res. 2016;22:5729-5737.
59. Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 2015;1:1325-1332.
60. Galvani E, Hogan, K, Gremel, G, et al. Influence of tumor mutation burden on response to anti-PD-1 treatment in murine models of melanoma [abstract]. Cancer Res. 2016;76(14 suppl):3207.
61. Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005;11:728-734.
62. Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373-377.
63. Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687-695.
64. Sharabi AB, Nirschl CJ, Kochel CM, et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res. 2015;3:345-355.
65. Slovin SF, Higano CS, Hamid O, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol. 2013;24:1813-1821.
66. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:700-712.
67. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925-931.
68. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1-10.
69. Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72:917-927.
70. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207:2187-2194.
71. Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13:273-390.
72. Adams S. Dramatic response of metaplastic breast cancer to chemo-immunotherapy [serial online]. NPJ Breast Cancer. 2017;3:8.
73. Loi S, Adams S, Schmid P, et al. Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab in metastatic triple-negative breast cancer. Ann Oncol. 2017;28(suppl 5):v605-v649.
74. Haricharan S, Bainbridge MN, Scheet P, Brown PH. Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data. Breast Cancer Res Treat. 2014;146:211-220.
75. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189-2199.
76. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124-128.
77. Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43-51.
78. Toyama T, Iwase H, Yamashita H, et al. Microsatellite instability in sporadic human breast cancers. Int J Cancer. 1996;68:447-451.
79. Anbazhagan R, Fujii H, Gabrielson E. Microsatellite instability is uncommon in breast cancer. Clin Cancer Res. 1999;5:839-844.
80. Adem C, Soderberg CL, Cunningham JM, et al. Microsatellite instability in hereditary and sporadic breast cancers. J Int Cancer. 2003;107:580-582.
81. Kuligina E, Grigoriev MY, Suspitsin EN, et al. Microsatellite instability analysis of bilateral breast tumors suggests treatment-related origin of some contralateral malignancies. J Cancer Res. Clin Oncol. 2007;133:57-64.
82. Plottel CS, Blaser MJ. Microbiome and malignancy. Cell Host Microbe. 2011;10:324-335.
83. Kwa M, Plottel CS, Blaser MJ, Adams S. The intestinal microbiome and estrogen receptor-positive female breast cancer [serial online]. J Natl Cancer Inst. 2016;108;dwj029.
84. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336:1268-1273.
85. Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350:1084-1089.
86. Vetizou M, Pitt JM, Daillere R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079-1084.